162490 20251017144601.0 doi 10.21037/tlcr-20-1055 sideral 145073 ART-2021-145073 deu Jarabo Sarceda, José Ramón Spanish Lung Cancer Group SCAT trial: surgical audit to lymph node assessment based on IASLC recommendations 2021 Access copy available to the general public Unrestricted Background: The Spanish Customized Adjuvant Therapy (SCAT) trial assessed the role of individualized adjuvant therapy in clinical N0 incidental pN1 and/or N2 non-small cell lung cancer (NSCLC) completely resected. We assessed surgical topics with an in-depth analysis of quality of lymphadenectomy based on International Association for the Study of Lung Cancer (IASLC) recommendations. Methods: Patients with information about lymphadenectomy available were included (N=451). Prospectively collected data about tumor, type of resection, and postoperative morbidity and quality of lymph node dissection (LND) were retrospectively evaluated. Role of lymph node assessment on survival was analyzed using Kaplan-Meier curves, using regression models to identify prognostic factors. Results: In 33.7%, 17.7% and 49.9% of cases, regions 7, 10 and 11 respectively were not assessed. In 21.1% of patients, less than three lymph node regions were biopsied, while in 19.6% of patients less than six lymph nodes were assessed. In 53,4% of patients only one N1 region was evaluated. From patients with positive N2, 8.9% had no N1 regions biopsied. Twenty-nine percent of patients with at least one N2 lymph node resected shown the highest region involved. Thirty-day postoperative mortality was unknown. Five-year overall survival (OS) was 61.7% (95% CI: 55.4–67.4%), 51.5% (95% CI: 39.2–62.4%) and 42.3% (95% CI: 32.1–52.2%) for patients with N1, N2 and N1+N2 disease, respectively (P<0.01). Both number of lymph nodes resected and number of lymph nodes involved by tumor were significantly related to prognosis. Conclusions: IASLC recommendations for surgical resections were not followed in a high proportion of surgical procedures. Hilar and mediastinal lymph node assessment and involvement showed to impact prognosis. Surgical issues such as postoperative mortality could not be evaluated owing to trial design. info:eu-repo/semantics/openAccess by-nc-nd https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es 4.726 2021 RESPIRATORY SYSTEM 24 / 66 = 0.364 2021 Q2 T2 ONCOLOGY 105 / 245 = 0.429 2021 Q2 T2 1.067 2021 Oncology 2021 Q2 4.8 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Bolufer Nadal, Sergio Mongil Poce, Roberto López de Castro, Pedro Moreno Balsalobre, Ramón Peñalver Cuesta, Juan Carlos Embún Flor, Raul Universidad de Zaragoza (orcid)0000-0003-0249-3104 Pac Ferrer, Joaquín Algar Algar, Francisco Javier Gámez García, Antonio Pablo Jiménez, Marcelo F. Sales-Badía, Jesús Gabriel Pereira, Eva Massuti, Bartomeu Provencio, Mariano Hernando Trancho, Florentino 1013 090 Universidad de Zaragoza Dpto. Cirugía Área Cirugía 10, 4 (2021), 1761-1772 Transl. lung cancer res. Translational lung cancer research 2218-6751 568948 http://zaguan.unizar.es/record/162490/files/texto_completo.pdf Versión publicada 2561049 http://zaguan.unizar.es/record/162490/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:162490 articulos driver 2025-10-17-14:14:15 ARTICLE